Syschem India Ltd. · BSE:SYSCHEM
Syschem India — Investor Presentation (May 2025)
25 slides from Syschem India's investor presentation, May 22, 2025
Slide 1: Investor's Presentation
SYSCHEM INDIA Investor's Presentation Presentation 2025
Slide 2: KEY PRODUCTS Pharmaceutical Strategy
Company Overview New Plant Evolution of API Products KEY PRODUCTS Pharmaceutical Strategy Key Goals Main Areas of Operation Model and Roadmap CAPACITY AND UTILISATION Proven Track Record Financials OUR CLIENTS About Our Team SAFE HARBOR STATEMENT Thank You
Slide 3: Company Overview
I SYSCHEM INDIA Company Overview ¢ Syschem (India) Limited (SIL) is a listed company engaged in the manufacturing of Bulk Drugs/Intermediates and contract manufacturing. It is owned and operated by a highly committed group of techno commercial with extensive experience in the bulkdrug business. AGEN
Slide 4: The Company is committed to its highly committed team
INDIA e The Company is committed to its highly committed team of techno-commercial specialists with considerable expertise in the bulk medicine market. Syschem India Limited nas established a firm presence in the business by providing their consumers with high-quality products and services. e The Co
Slide 5: New Plant
NEW PLANT INDIA SYSCHEM W
Slide 6: WSHOSAS S
4 SYSCHEM INDIA : cones AGENDA
Slide 7: Key Products
S BIBSSED) KEY PRODUCTS AMOXICILLIN AMPICIILLIN A broad-spectrum penicillin A penicillin antibiotic effective antibiotic used to treat bacterial against both gram-positive and infections some gram-negative bacteria. CLOXACILLIN DICLOXACILLIN A penicillinase-resistant penicillin A beta-lactam antibio
Slide 8: Pharmaceutical Strategy
YS SYSCHEM INDIA Pharmaceutical Stratesy Innovating for Future Success AGENDA
Slide 9: Strategic Vision & Evolution
4 SYSCHEM INDIA STRATEGIC VISION & EVOLUTION OUR DIRECTION Largely the capacity expansions Increase in distribution network Adding Product Ranges SS
Slide 10: Our Strategic Vision Explained
S SYSCHEM INDIA Our Strategic Vision Explained SIL's vision is toboost production of our existing — 1 products while expanding our offers by creating various intermediates that are now imported from China for the API industry. Over the next 2-3 years, we hope to minimise our reliance on imports and
Slide 11: High Growth Potential & Shareholder Value Creation
S SYSCHEM INDIA HIGH GROWTH POTENTIAL & SHAREHOLDER VALUE CREATION Our company’s rapid .growth—fueled by innovation, elobal expansion, and robust product pipelines— demonstrates our ability to meet rising healthcare demands and successfully enter new markets. This sustained momentum translates into
Slide 12: We aim to drive year-on-year growth in production
"We aim to drive year-on-year srowth tn production to meet our Strategic objectives.” AGENDA
Slide 13: Key Goals
YoY improved quality. Improved market position on YoY basis. sense" KEY GOALS Built up new plant of amoxicilin and ampicilin , Planning to enter in 2 023 =-25 international market with necessary approvals. S SYSCHEM INDIA AGENDA
Slide 14: Main Areas of Operation
Sace® Nain Areas of Operation | The company has a diverse range of intermediate items in the pharmaceuticals industry that are created chemically. Jammu and The company has established a foothold in India and the international market; its products have been exported to Latin America, Africa, Thailan
Slide 15: Supply Zone
4 SYSCHEM INDIA Main Areas of Operation SUPPLY ZONE 24% Expanding operations and improving customer satisfaction are core goals for any thriving business. As we continue to grow, our focus remains on understanding and anticipating the needs of our customers, ensuring that we deliver unparalleled ser
Slide 16: Innovation Roadmap Journey
eae SYSCHEM Innovation Roadmap Journey INDIA e \ cio \ ‘\ \ ~ = a“ Business Model Strategic Shift to Performance Current Position Evolution Independent Sales Highlights & Future Outlook Operated under a contract Transitioned from contract Recorded highest-ever topline Built a strong customer base an
Slide 17: Proven Track Record of Production
4 SYSCHEM INDIA PROVEN TRACK RECORD OF PRODUCTION Excellence in Delivery Every Time
Slide 18: Proven Track Record of Topline
INDIA Proven Track | Record of Topline Showcasing consistent growth strategies
Slide 19: Capacity and Utilisation
2022-23 2023-24 @ 2024-25 Capacity and Utlisation CAPACITY AND = 2022-23 2023-24 FY @ Utilisation %age 2024-25 UTILISATION Utilisation %age AGENDA 2022-23 2023-24 2024-25 FY
Slide 20: Financials
V7 @ 2022-23 @ EBIDTA 2023-24 @ 2024-25 SYSCHEM INDIA 2024-25 402 2022-23 890 FINANCIALS = ¢4cenos 2022-23 2023-24 2024-25
Slide 21: Our Clients
Bm LABORATE | fe ™ Aimalayva £ SINCE 1930 a OUR CLIENTS AAGYA BIOTECH Sc ot t Ed il Complementing life AGENDA RA Medico Remedies Ltd
Slide 22: About Our Team
“About Our Team SYSCHEM The people behind the company's achievements At the heart of our pharmaceutical company lies an exceptional team that embodies innovation, collaboration, and commitment to excellence. Our diverse group of professionals, ranging from "The remarkable expansion in revenue has ch
Slide 23: Safe Harbor Statement
INDIA SAFE HARBOR STATEMENT This Information Memorandum has been prepared by the Company based on information and data which the Company considers reliable. However, the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accurac
Slide 24: YS SYSCHEM
YS SYSCHEM INDIA Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are
Slide 25: Thank You
\ 4 THANK YOU A Presentation by - S SYSCHEM INDIA Factory at. : Village Bargodam, Tehsil Kalka, Dist. Panchkula, Haryana-133302 Corp Office. : 825, FF, NAC Manimajra , Chandigarh-161001 Telephone no : 0172-5070471 Email Id : [email protected]